Drug Profile
Research programme: topoisomerase inhibitors - BTG
Alternative Names: Topoisomerase inhibitors research programme - BTGLatest Information Update: 21 Aug 2019
Price :
$50
*
At a glance
- Originator BTG
- Class
- Mechanism of Action DNA topoisomerase I inhibitors; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 19 Aug 2019 BTG has been acquired by Boston Scientific Corporation
- 07 May 2007 No development reported - Preclinical for Cancer in United Kingdom (unspecified route)
- 08 Mar 2004 Topoisomerase inhibitors research programme is available for licensing in Europe, North America and Japan (\http://www.btgplc.com\)